Chief executives of mRNA vaccine groups earn $100m in pandemic pay
Bosses of Pfizer, BioNTech and Moderna also see paper wealth grow as share prices surge
Moderna ready to develop Omicron booster in weeks, says chief executive
The company made between 700m and 800m Covid-19 vaccine doses this year
Q&A: All you need to know on getting the Moderna vaccine as a booster
Moderna will be the main vaccine administered over coming weeks to over-60s, over-50s, healthcare workers and younger people in vulnerable groups
Omicron: EU states urged to boost genome sequencing as Ireland lags behind
Moderna chief warns existing vaccines will struggle with latest coronavirus variant
European stocks tumble on doubts about vaccine efficacy against Omicron
Global stocks hit by Moderna chief’s comments on existing vaccines
Moderna seeks EU authorisation for Covid-19 vaccine in young kids
Vaccine was authorised for use in 12-17 year olds by EMA in July
Moderna plans mRNA vaccine factory in Africa
Facility would make up to 500m doses per year, including Covid-19 shots
Moderna says Covid-19 vaccine 93% effective six months after jab
US vaccine group earns €2.34bn on sales of €3.8bn as it plans for booster shots
How well do Covid-19 vaccines protect against the Delta variant?
Most agree that the leading shots still offer strong protection against severe disease
Moderna says Covid-19 vaccine highly effective in 12-17 year-olds
Data paves way for applications to regulators for approval by June
Moderna reports first-ever quarterly profit with €1.4bn Covid sales
Proposed patent waiver ‘will not help supply vaccines to the world any faster’, says CEO
Altered Moderna vaccine ‘neutralises Covid variants in trials’
Boosters effective in small trial against South African and Brazilian coronavirus variants
Moderna plans to produce up to 3bn Covid-19 vaccine doses in 2022
Phram company plans to boost output at factories in US, Europe
EU agrees deal for millions of additional Covid-19 vaccine doses
Commission also putting funds into studying and responding to new variants of disease
Moderna seeks US and European clearance for Covid vaccine
New analysis confirms 94% efficacy and strong two-month safety data
Pfizer-BioNTech and Moderna begin late-stage Covid-19 vaccine trials
Companies expect approvals as early as October if vaccines deliver on early promise
Covid-19 vaccine hopes soar as Moderna shows promise in early study
Shares jump 25% as initial results show vaccine produces antibodies to coronavirus
Testing starts in human trial of coronavirus vaccine
Vaccine will not be available for another year even if it is proved safe and effective
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices